| Name | Title | Contact Details |
|---|
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.
Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.
Valcour Strategic Group is a Peru, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.